Cytokines and Cardiac Contractile Function
1997; Lippincott Williams & Wilkins; Volume: 95; Issue: 4 Linguagem: Inglês
10.1161/01.cir.95.4.778
ISSN1524-4539
AutoresRalph A. Kelly, Thomas W. Smith,
Tópico(s)Nitric Oxide and Endothelin Effects
ResumoHomeCirculationVol. 95, No. 4Cytokines and Cardiac Contractile Function Free AccessResearch ArticleDownload EPUBAboutView EPUBSections ToolsAdd to favoritesDownload citationsTrack citationsPermissions ShareShare onFacebookTwitterLinked InMendeleyReddit Jump toFree AccessResearch ArticleDownload EPUBCytokines and Cardiac Contractile Function Ralph A. Kelly and Thomas W. Smith Ralph A. KellyRalph A. Kelly the Cardiovascular Division, Department of Medicine, Brigham and Women's Hospital and Harvard Medical School, Boston, Mass. and Thomas W. SmithThomas W. Smith the Cardiovascular Division, Department of Medicine, Brigham and Women's Hospital and Harvard Medical School, Boston, Mass. Originally published18 Feb 1997https://doi.org/10.1161/01.CIR.95.4.778Circulation. 1997;95:778–781A working understanding of the molecular and cell biology of inflammatory cytokines is of growing importance to both cardiovascular scientists and practicing clinicians. Accumulating evidence indicates that these locally acting polypeptide mediators, or "autacoids," play a role not only in the pathogenesis of atherosclerosis and in the cardiac dysfunction that accompanies systemic sepsis, viral myocarditis, and cardiac allograft rejection but also in advanced heart failure syndromes resulting from diverse pathogenic insults. ("Autacoid" is derived from the Greek words autos ["self"] and akos ["remedy"]; autacoids are locally acting, biologically active agents [both peptides and nonpeptides] that are distinct from neurotransmitters and hormones in the circulation.1 ) More than 25 years ago, Lefer and Rovetto2 reported that the sera of septic patients and experimental animals contained a "myocardial depressant factor," the molecular nature of which has eluded definitive identification in the intervening years. During the past decade, Parrillo and colleagues34 used intact animals and in vitro isolated heart cell preparations to systematically investigate the factors that contribute to myocardial depression in systemic sepsis (ie, the systemic inflammatory response syndrome) and concluded that TNF-α and IL-1β were shown to be present in the sera of septic patients and are responsible for most, if not all, of the reversible cardiac depression often seen with this syndrome. These data are consistent with earlier reports (reviewed in Levine et al5 ) that soluble inflammatory mediators in medium conditioned by activated immunocytes altered the contractile responsiveness of beating cardiac muscle cells to β-adrenergic agonists, an effect that could be mimicked in this in vitro preparation by recombinant TNF-α or IL-1β. Interest in these findings has been amplified by reports of elevated circulating as well as intracardiac TNF-α levels in patients with heart failure.678910Systemic infusions of one or more recombinant cytokines such as TNF-α and IL-1β in intact animal preparations have yielded varying results. Although some studies1112 have observed a gradual decline in cardiac contractile function in dogs injected with recombinant human TNF-α, Murray and Freeman13 identified a biphasic effect in a conscious, chronically instrumented dog model. In this preparation, recombinant human TNF-α increased left ventricular contractile function within minutes, followed by a gradual, profound decline in ventricular systolic function that took several hours to manifest. Many of the differences in the reported effects of recombinant cytokines in both intact animals and in vitro models are likely due to differences in the specific experimental models and procedures that were used. It is relevant, as emphasized by Nathan and Sporn,14 that in most physiological contexts, inflammatory cytokines such as TNF-α and IL-1β are locally acting autocrine (acting on the cell of origin), paracrine (acting on neighboring cells), or juxtacrine (acting on adjacent cells) agents whose biological activity is determined not only by the specific target cell type but also the intracellular milieu or biological context in which a cytokine acts. Thus, results obtained with systemic or in vitro administration of a specific recombinant cytokine must be interpreted cautiously and with this caveat in mind.Several reports over the past 5 years have shown an increase in plasma as well as myocardial TNF-α in patients with advanced heart failure caused by ischemic or idiopathic cardiomyopathies.678910 There is a concomitant increase in patients with heart failure in plasma levels of soluble TNF-α receptors (ie, sTNF-RI[p55] and sTNF-RII[p75]), which appear to bind and neutralize most, if not all, circulating TNF-α.151617 However, as emphasized above, it is the effect of locally synthesized myocardial TNF-α acting within a pathophysiological context that likely includes additional cytokines and other peptide autacoids that may contribute to ongoing myocardial injury and dysfunction in the chronic heart failure syndrome.Those cytokines directly implicated to date in mediating myocardial depression in systemic sepsis and other forms of cardiac dysfunction include, in addition to TNF-α and IL-1β, IL-2, IL-6, and IFN-γ (see Figure). Recent research has begun to clarify some of the intracellular signaling mechanisms that contribute to cardiac myocyte contractile dysfunction. IL-1β has been shown to rapidly suppress voltage-dependent Ca2+ current (ICa-L) in adult rat ventricular myocytes.18 Consistent with these data, Mann and colleagues19 demonstrated that low-to-moderate concentrations of recombinant human TNF-α (ie, ≤200 U/mL) resulted in a rapid, reversible decrease in peak systolic intracellular calcium that was unaffected by inhibitors of NO or eicosanoid-dependent signaling pathways. Additional data from this laboratory have implicated a TNF-RI receptor activation of a neutral sphingomyelinase pathway in cardiac myocytes,20 analogous to activation of this signaling pathway by TNF-α in adipocytes.21In contrast, substantially higher concentrations of recombinant human TNF-α (≥1000 U/mL) have been shown by Finkel et al22 and by Goldhaber et al23 to result in rapid and reversible declines in contractile function of isolated hamster papillary muscles or of adult guinea pig and rabbit ventricular myocytes, respectively, a decline that could be abrogated in both preparations by NOS inhibitors. In both experimental models, the effect of recombinant human TNF-α was apparent within minutes, implicating activation of the constitutively expressed NOS isoform in cardiac myocytes (ie, eNOS or NOS3; for a review, see Kelly et al24 ). This decline in velocity of shortening with high concentrations of TNF-α in isolated myocytes was unaccompanied by a significant change in diastolic or systolic [Ca2+]i activity, implicating a NO-mediated decrease in the sensitivity of the myofilaments to [Ca2+]i.23 This proposed mechanism is consistent with data reported by Shah et al25 and with preliminary data from our laboratory (D.M. Kaye, S. Wiviott, X. Han, L. Belhassen, R.A. Kelly, T.W. Smith, unpublished data, 1997) that demonstrate that either activation of eNOS in cardiac myocytes or agents that mimic selected components of signal transduction cascades downstream of NO appear to desensitize cardiac myofilaments to [Ca2+]i, an effect that may be due at least in part to phosphorylation of troponin I. Although of considerable mechanistic interest, the physiological or clinical relevance of the high concentrations of cytokines used in some studies2223 remains to be determined.After several hours of exposure to inflammatory cytokines and/or to cell wall components of Gram-positive or -negative bacteria, cellular constituents with the heart, including the microvascular and endocardial endothelium, vascular smooth muscle, and cardiac myocytes, express a cytokine-inducible "high output" isoform of NOS (iNOS or NOS2; for a review, see Kelly et al24 ). The cytokines most closely associated with iNOS induction (ie, TNF-α, IL-1β, and IL-6) are also known to be mediators of "innate" immunity, whereas IFN-γ, a T cell–derived cytokine, accelerates iNOS induction in many cell types, including cardiac myocytes and the endothelium of the microvasculature.2627 In addition to induction of iNOS itself, these cytokines also enhance or initiate the expression of proteins essential for maximal iNOS activity in cardiac myocytes and cardiac microvascular endothelium, including cationic amino acid transporters necessary for uptake of the NO precursor l-arginine and enzymes necessary for the production of tetrahydrobiopterin, a cofactor essential for iNOS dimerization and activation.282930The induction of this NOS isoform in the heart, as in most other tissues, has been included by Nathan31 in the category of innate immune responses, a phylogenetically primitive but rapidly activated form of host defense that can be mounted more quickly than the highly selective "adaptive" immune response that requires clonal amplification of antigen-specific lymphocytes. iNOS induction by cytokines within the heart, as in other tissues, undoubtedly plays an important role in host defense to some pathogens. Lowenstein et al32 demonstrated that mice infected with coxsackievirus B3 and concurrently administered drugs that inhibit NOS activity had higher viral titers and mortality than similarly infected mice not receiving these agents. In addition, mice lacking a functional iNOS gene (ie, iNOS "knockout" mice) were much more susceptible than wild-type animals to lethal injection with facultative intracellular and opportunistic pathogens.3334 However, these iNOS knockout animals were less likely to develop a fatal septic shock–like syndrome after an intraperitoneal injection of lipopolysaccharide, supporting the view that iNOS induction plays an important role in the hemodynamic and metabolic sequelae of systemic sepsis.These data are consistent with a number of recent reports (reviewed in References 24, 35, and 36) that increased iNOS expression in cardiac myocytes and in microvascular and endocardial endothelial cells, which combined with infiltrating inflammatory cells account for most NO production after regional or global iNOS induction in the heart, markedly suppresses basal and β-adrenergic agonist–stimulated myocardial inotropic responsiveness. The decline in myocardial contractile function after iNOS induction by cytokines is likely due to both NO-dependent activation of guanylyl cyclase and increased intracellular cGMP, as well as to non–cGMP-dependent effects of NO. As in other cell types, NO may either directly or indirectly alter formation of S-nitrosothiols affect cardiac myocyte energetics and the function of specific sarcolemmal ion channels.373839 Finally, not all physiological sequelae of iNOS activation may be reversible. In response to IL-1β, TNF-α, and IFN-γ, Pinsky et al40 documented that iNOS induction by these cytokines in adult rat ventricular myocytes resulted in an increase in myocyte death. Subsequent reports from this laboratory have implicated induction by these cytokines of a NO-dependent apoptotic pathway in these cells.4142A pathophysiological role for iNOS may not be limited to conditions characterized by systemic or intracardiac iNOS induction, such as systemic sepsis, inflammatory myocarditis, or cardiac allograft rejection. Two recent reports4344 indicate that iNOS expression is increased in the myocardium of patients with advanced heart failure, whether caused by ischemic heart disease, idiopathic cardiomyopathy, or valvular disease, confirming and extending the results of an earlier study.45 These data from humans with heart failure have appeared concurrently with reports that induction of iNOS by cytokines in cardiac myocytes is enhanced and sustained by increases in intracellular cAMP and activation of diacylglycerol-regulated protein kinase C after exposure to catecholamines or peptide autacoids such as angiotensin II and arginine vasopressin, all of which are agents that are known to be important components of the neurohumoral activation characteristic of heart failure.4647484950Despite the weight of circumstantial evidence reviewed above, there are no data that firmly establish an important role for iNOS induction in the pathophysiology of clinical heart failure. Nevertheless, the documentation of high intramyocardial and plasma levels of TNF-α in humans with heart failure, in combination with catecholamines and peptide autacoids known to enhance iNOS expression and activity in cardiac myocytes, indicates that this is an important hypothesis to be tested. The substantial mortality associated both with systemic sepsis and chronic heart failure reminds clinicians as well as basic and clinical investigators that the stakes are high.Selected Abbreviations and Acronyms[Ca2+]i=intracellular calcium concentrationIFN-γ=interferon-γIL=interleukiniNOS=inducible nitric oxide synthaseNOS=nitric oxide synthaseTNF-α=tumor necrosis factor-αThe opinions expressed in this editorial are not necessarily those of the editors or of the American Heart Association.Download figureDownload PowerPoint Figure 1. Potential mechanisms and mediators by which cytokines may contribute to cardiac myocyte contractile dysfunction. Inflammatory mediators, including bacterial cell wall components such as lipopolysaccharide (endotoxin), can induce generation of specific cytokines and expression of iNOS in macrophages and endothelial cells. These cells, as well as activated T cells and natural killer (NK) cells, subsequently generate additional cytokines that induce contractile dysfunction in cardiac myocytes by both NO-dependent and NO-independent mechanisms. Recent evidence (see text) has also implicated these cytokines and increased iNOS expression in the pathogenesis of heart failure.This work was supported by a grant from the National Heart, Lung, and Blood Institute (HL-52320). The authors thank Drs Abul K. Abbas and Daniel I. Simon for their thoughtful reviews of the manuscript.FootnotesCorrespondence to Ralph A. Kelly, MD, Cardiovascular Division, Brigham and Women's Hospital, 75 Francis St, Boston, MA 02115. E-mail [email protected] References 1 Serafin WE, Babe KS. Autacoids: drug therapy and inflammation. In: Hardman JG, Limbird LE, eds. Goodman and Gilman's The Pharmacological Basis of Therapeutics. 9th ed. New York, NY: McGraw-Hill; 1996, section V.Google Scholar2 Lefer A, Rovetto M. Influence of a myocardial depressant factor on physiologic properties of cardiac muscle. Proc Soc Exp Biol.1970; 134:269-273.CrossrefMedlineGoogle Scholar3 Parrillo JE. Pathogenetic mechanism of septic shock. N Engl J Med.1993; 328:1471-1477.CrossrefMedlineGoogle Scholar4 Kumar A, Thota V, Dee L, Olson J, Uretz E, Parrillo JE. Tumor necrosis factor-α and interleukin-1β are responsible for in vitro myocardial cell depression induced by human septic shock serum. J Exp Med.1996; 183:949-958.CrossrefMedlineGoogle Scholar5 Lange LG, Schreiner GF. Immune cytokines and cardiac disease. Trends Cardiovasc Med.1992; 2:145-151.CrossrefMedlineGoogle Scholar6 Levine B, Kalman J, Mayer L, Fillit HM, Packer M. Elevated circulating levels of tumor necrosis factor in severe chronic heart failure. N Engl J Med.1990; 223:236-241.CrossrefGoogle Scholar7 McMurray J, Abdullah I, Dargie HJ, Shapiro D. Increased concentrations of tumor necrosis factor in 'cachectic' patients with severe chronic heart failure. Br Heart J.1991; 66:356-358.CrossrefMedlineGoogle Scholar8 Matsumori A, Yamada T, Suzuki H, Matoba Y, Sasayama S. Increased circulating cytokines in patients with myocarditis and cardiomyopathy. Br Heart J.1994; 72:561-566.CrossrefMedlineGoogle Scholar9 Dutka DP, Elborn JS, Delamere F, Shale DJ, Morris GK. Tumor necrosis factor-α in severe congestive cardiac failure. Br Heart J.1993; 70:141-143.CrossrefMedlineGoogle Scholar10 Katz SD, Rao R, Berman JW, Schwarz M, Demopoulos L, Bijou R, LeJemtel TH. Pathophysiological correlates of increased serum tumor necrosis factor in patients with congestive heart failure: relation to nitric oxide–dependent vasodilation in the forearm circulation. Circulation.1994; 90:12-16.CrossrefMedlineGoogle Scholar11 Pagani FD, Baker LS, Hsi C, Knox M, Fink MP, Visner MS. Left ventricular systolic and diastolic dysfunction after infusion of tumor necrosis factor-α in conscious dogs. J Clin Invest.1992; 90:389-398.CrossrefMedlineGoogle Scholar12 Natanson C, Eichenholz PW, Danner RL, Eichhacker PQ, Hoffman WD, Kuo GC, Banks SM, MacVittie TJ, Parrillo JE. Endotoxin and tumor necrosis factor challenge in dogs simulate the cardiovascular profile of human septic shock. J Exp Med.1989; 169:823-832.CrossrefMedlineGoogle Scholar13 Murray DR, Freeman GL. Tumor necrosis factor-α induces a biphasic effect on myocardial contractility in conscious dogs. Circ Res.1996; 78:154-160.CrossrefMedlineGoogle Scholar14 Nathan C, Sporn M. Cytokines in context. J Cell Biol.1991; 113:981-986.CrossrefMedlineGoogle Scholar15 Torre-Amione G, Kapadia S, Lee J, Bies RD, Lebovitz R, Mann DL. Expression and functional significance of tumor necrosis factor receptors in human myocardium. Circulation.1995; 92:1487-1493.CrossrefMedlineGoogle Scholar16 Ferrari R, Bachetti T, Confortini R, Opasich C, Febo O, Corti A, Cassani G, Visioli O. Tumor necrosis factor–soluble receptors in patients with various degrees of congestive heart failure. Circulation.1995; 92:1479-1486.CrossrefMedlineGoogle Scholar17 Torre-Amione G, Kapadia S, Lee J, Durand J-B, Bies RD, Young JB, Mann DL. Tumor necrosis factor-α and tumor necrosis factor receptors in the failing human heart. Circulation.1996; 93:704-711.CrossrefMedlineGoogle Scholar18 Liu S, Schreur KD. G protein-mediated suppression of L-type Ca2+ current by interleukin-1β in cultured rat ventricular myocytes. Am J Physiol.1995; 268:C339-C349.CrossrefMedlineGoogle Scholar19 Yokoyama T, Vaca L, Rossen RD, Durante W, Hazarika P, Mann DL. Cellular basis for the negative inotropic effects of tumor necrosis factor-α in the adult mammalian heart. J Clin Invest.1993; 92:2303-2312.CrossrefMedlineGoogle Scholar20 Hakan O, Dorn GW, Mann DL. Sphingosine mediates the immediate negative inotropic effects of tumor necrosis factor-α in the adult mammalian cardiac myocyte. J Biol Chem. In press.Google Scholar21 Peraldi P, Hotamisligil GS, Buurman WA, White MF, Spiegelman BM. Tumor necrosis factor (TNF)-α inhibits insulin signaling through stimulation of the p55 TNF receptor and activation of sphingomyelinase. J Biol Chem.1996; 271:13018-13022.CrossrefMedlineGoogle Scholar22 Finkel MS, Oddis CV, Jacob TD, Watkins SC, Hattler BG, Simmons RL. Negative inotropic effects of cytokines on the heart mediated by nitric oxide. Science.1992; 257:387-389.CrossrefMedlineGoogle Scholar23 Goldhaber JL, Kim KH, Natterson PD, Lawrence T, Yang P, Weiss JN. Effects of TNF-α on [Ca2+]i and contractility in isolated adult rabbit ventricular myocytes. Am J Physiol.1996; 271:H1449-H1455.CrossrefMedlineGoogle Scholar24 Kelly RA, Balligand J-L, Smith TW. Nitric oxide and cardiac function. Circ Res.1996; 79:363-380.CrossrefMedlineGoogle Scholar25 Shah AM, Spurgeon HA, Sollott SJ, Talo A, Lakatta EG. 8-Bromo-cGMP reduces the myofilament response to Ca2+ in intact cardiac myocytes. Circ Res.1994; 74:970-978.CrossrefMedlineGoogle Scholar26 Balligand J-L, Ungureanu-Longrois D, Simmons WW, Pimental D, Malinski TA, Kapturczak M, Taha Z, Lowenstein CJ, Davidoff AJ, Kelly RA, Smith TW, Michel T. Cytokine-inducible nitric oxide synthase (iNOS) expression in cardiac myocytes: characterization and regulation of iNOS expression and detection of iNOS activity in single cardiac myocytes in vitro. J Biol Chem.1994; 269:27580-27588.CrossrefMedlineGoogle Scholar27 Balligand J-L, Ungureanu-Longrois D, Simmons WW, Kobzik L, Lowenstein CJ, Lamas S, Kelly RA, Smith TW, Michel T. Induction of NO synthase in rat cardiac microvascular endothelial cells by IL-1β and IFN-γ. Am J Physiol.1995; 268:H1293-H1303.MedlineGoogle Scholar28 Simmons WW, Closs EI, Cunningham JM, Smith TW, Kelly RA. Cytokines and insulin induce cationic amino acid transporter (CAT) expression in cardiac myocytes: regulation of L-arginine transport and NO production by CAT-1, CAT-2A, and CAT-2B. J Biol Chem.1996; 271:11694-11702.CrossrefMedlineGoogle Scholar29 Oddis CV, Finkel MS. NF-κB and GTP cyclohydrolase regulate cytokine-induced nitric oxide production by cardiac myocytes. Am J Physiol.1996; 270:H1864-H1868.CrossrefMedlineGoogle Scholar30 Simmons WW, Ungureanu-Longrois D, Smith GK, Smith TW, Kelly RA. Glucocorticoids regulate inducible nitric oxide synthase (NOS2) by inhibiting tetrahydrobiopterin synthesis and L-arginine transport. J Biol Chem.1996; 271:23928-23937.CrossrefMedlineGoogle Scholar31 Nathan C. Natural resistance and nitric oxide. Cell.1995; 82:873-876.CrossrefMedlineGoogle Scholar32 Lowenstein CJ, Hill SL, Lafond-Walker A, Wu J, Allen G, Landavere M, Rose NR, Herskowitz A. Nitric oxide inhibits viral replication in murine myocarditis. J Clin Invest.1996; 97:1837-1843.CrossrefMedlineGoogle Scholar33 Wei X-QW, Charles IG, Smith A, Ure J, Feng G-J, Huang F, Xu D, Muller W, Moncada S, Liew FY. Altered immune responses in mice lacking inducible nitric oxide synthase. Nature.1995; 375:408-411.CrossrefMedlineGoogle Scholar34 MacMicking JD, Nathan C, Hom G, Chartrain N, Fletcher DS, Trumbauer M, Stevens K, Xie Q, Sokol K, Hutchinson N, Chen H, Mudgett JS. Altered responses to bacterial infection and endotoxic shock in mice lacking inducible nitric oxide synthase. Cell.1995; 81:641-650.CrossrefMedlineGoogle Scholar35 Ungureanu-Longrois D, Balligand J-L, Kelly RA, Smith TW. Myocardial contractile dysfunction in the systemic inflammatory response syndrome: role of a cytokine-inducible nitric oxide synthase in cardiac myocytes. J Mol Cell Cardiol.1995; 27:155-167.CrossrefMedlineGoogle Scholar36 Shen W, Xu X, Ochoa M, Zhao G, Wolin MS, Hintze TH. Role of nitric oxide in the regulation of oxygen consumption in conscious dogs. Circ Res.1994; 75:1086-1095.CrossrefMedlineGoogle Scholar37 Gross WL, Bak MI, Ingwall JS, Arstall MA, Balligand J-L, Smith TW, Kelly RA. Nitric oxide regulates rat heart contractile reserve and inhibits creatine kinase. Proc Natl Acad Sci U S A.1996; 93:5604-5609.CrossrefMedlineGoogle Scholar38 Campbell DL, Stamler JS, Strauss HC. Redox modulation of L-type calcium channels in ferret ventricular myocytes: mechanisms of dual indirect and direct modulation by nitric oxide and S-nitrosothiols. J Gen Physiol.1996; 108:277-293.CrossrefMedlineGoogle Scholar39 Pinsky DJ, Cai B, Yang X, Rodriguez C, Sciacca RR, Cannon PJ. The lethal effects of cytokine-induced nitric oxide on cardiac myocytes are blocked by nitric oxide synthase antagonism or transforming growth factor-β. J Clin Invest.1995; 95:677-685.CrossrefMedlineGoogle Scholar40 Pinsky DJ, Yang Y, Aji W, Szabolcs M, Liao H, Sciacca RR, Cannon PJ. Nitric oxide induces apoptosis of adult rat cardiac myocytes. Circulation. 1995;92(suppl I):I-565. Abstract.Google Scholar41 Szabolcs M, Michler RE, Yang X, Aji W, Roy D, Athan E, Sciacca RR, Minanov OP, Cannon PJ. Apoptosis of cardiac myocytes during cardiac allograft rejection: relation to induction of nitric oxide synthase. Circulation.1996; 94:1665-1673.CrossrefMedlineGoogle Scholar42 Haywood GA, Tsao PS, von der Leyen HE, Mann MJ, Keeling PJ, Trindade PT, Lewis NP, Byme CD, Rickenbacher PR, Bishopric NH, Cooke JP, McKenna WJ, Fowler MB. Expression of inducible nitric oxide synthase in human heart failure. Circulation.1996; 93:1087-1094.CrossrefMedlineGoogle Scholar43 Habib FM, Springall DR, Davies GJ, Oakley CM, Yacoub MH, Polak JM. Tumor necrosis factor and inducible nitric oxide synthase in dilated cardiomyopathy. Lancet.1996; 347:1151-1155.CrossrefMedlineGoogle Scholar44 deBelder AJ, Radomski MW, Why HJF, Richardson PJ, Bucknall CA, Salas E, Martin JF, Moncada S. Nitric oxide synthase activities in human myocardium. Lancet.1993; 341:84-85.CrossrefMedlineGoogle Scholar45 Ikeda U, Maeda Y, Kawahara Y, Yokoyama M, Shimada K. Angiotensin II augments cytokine-stimulated nitric oxide synthesis in rat cardiac myocytes. Circulation.1995; 92:2683-2689.CrossrefMedlineGoogle Scholar46 Ikeda U, Murakami Y, Kanbe T, Shimada K. α-Adrenergic stimulation enhances inducible nitric oxide synthase expression in rat cardiac myocytes. J Mol Cell Cardiol.1996; 28:789-795.CrossrefMedlineGoogle Scholar47 Oddis CV, Simmons RL, Hattler BG, Finkel MS. cAMP enhances inducible nitric oxide synthase mRNA stability in cardiac myocytes. Am J Physiol.1995; 269:H2044-H2050.MedlineGoogle Scholar48 Ikeda U, Yamamoto K, Ichida M, Ohkawa F, Murata M, Iimura O, Kusano E, Asano Y, Shimada K. Cyclic AMP augments cytokine-stimulated nitric oxide synthesis in rat cardiac myocytes. J Mol Cell Cardiol.1996; 28:789-795.CrossrefMedlineGoogle Scholar49 Oddis CV, Simmons RL, Hattler BG, Finkel MS. Protein kinase A activation is required for IL-1 induced nitric oxide production by cardiac myocytes. Am J Physiol.1996; 271:C429-C434.CrossrefMedlineGoogle Scholar50 Hirono S, Omedul Islam M, Nakazawa M, Yoshida Y, Kodama M, Shibata A, Izumi T, Imai S. Expression of inducible nitric oxide synthase in rat experimental autoimmune myocarditis with special reference to changes in cardiac hemodynamics. Circ Res..1997; 80:11-20.CrossrefMedlineGoogle Scholar Previous Back to top Next FiguresReferencesRelatedDetailsCited By Saraf A, Rampoldi A, Chao M, Li D, Armand L, Hwang H, Liu R, Jha R, Fu H, Maxwell J and Xu C (2021) Functional and molecular effects of TNF-α on human iPSC-derived cardiomyocytes, Stem Cell Research, 10.1016/j.scr.2021.102218, 52, (102218), Online publication date: 1-Apr-2021. (Shoma Fujiya) 藤, (Takashi Mato) 間, (Yuri Furuhashi) 古, (Tomotaka Takanosu) 鷹, (Yasutaka Tanaka) 田, (Yoshimitsu Izawa) 伊 and (Hiroshi Nishino) 西 (2021) 耳管通気を契機に重症呼吸不全を来した1例(A case of severe respiratory failure triggered by eustachian tube inflation that required life–saving venovenous extracorporeal membrane oxygenation), Nihon Kyukyu Igakukai Zasshi: Journal of Japanese Association for Acute Medicine, 10.1002/jja2.12502, 32:1, (24-29), Online publication date: 1-Jan-2021. Çakır H, Kanat S, Çakır H and Tenekecioğlu E (2021)(2021) Níveis mais Baixos de Fetuína-A Sérica estão Associados a um Maior Risco de Mortalidade em Dez Anos em Pacientes com Infarto do Miocárdio por Supradesnivelamento do Segmento ST, Arquivos Brasileiros de Cardiologia, 10.36660/abc.20201057, Online publication date: 17-Nov-2021., Online publication date: 17-Nov-2021. Duncan S, Gao S, Sarhene M, Coffie J, Linhua D, Bao X, Jing Z, Li S, Guo R, Su J and Fan G (2020) Macrophage Activities in Myocardial Infarction and Heart Failure, Cardiology Research and Practice, 10.1155/2020/4375127, 2020, (1-16), Online publication date: 22-Apr-2020. Gehrke N and Schattenberg J (2020) Metabolic Inflammation—A Role for Hepatic Inflammatory Pathways as Drivers of Comorbidities in Nonalcoholic Fatty Liver Disease?, Gastroenterology, 10.1053/j.gastro.2020.02.020, 158:7, (1929-1947.e6), Online publication date: 1-May-2020. Lackner I, Weber B, Knecht D, Horst K, Relja B, Gebhard F, Pape H, Huber-Lang M, Hildebrand F and Kalbitz M (2020) Cardiac Glucose and Fatty Acid Transport After Experimental Mono- and Polytrauma, Shock, 10.1097/SHK.0000000000001400, 53:5, (620-629), Online publication date: 1-May-2020. Monaco F, Gaia B, Cristina M and Monica D (2019) Physiopathology of Intraoperative Visceral Ischemia and Anesthesiological Management of Supravisceral Aortic Clamping Visceral Vessels and Aortic Repair, 10.1007/978-3-319-94761-7_14, (147-161), . Hussain N, Hussain F, Malik A, Rizvi M, Patel P and Chittivelu S (2018) A devastating cardiovascular event in an adult cystic fibrosis patient: An unforeseen outcome of increasing life expectancy, Respiratory Medicine Case Reports, 10.1016/j.rmcr.2018.09.013, 25, (233-234), . Eising J, van der Ent C, Teske A, Vanderschuren M, Uiterwaal C and Meijboom F (2018) Young patients with cystic fibrosis demonstrate subtle alterations of the cardiovascular system, Journal of Cystic Fibrosis, 10.1016/j.jcf.2017.12.009, 17:5, (643-649), Online publication date: 1-Sep-2018. Bro-Jeppesen J, Johansson P, Kjaergaard J, Wanscher M, Ostrowski S, Bjerre M and Hassager C (2017) Level of systemic inflammation and endothelial injury is associated with cardiovascular dysfunction and vasopressor support in post-cardiac arrest patients, Resuscitation, 10.1016/j.resuscitation.2017.09.019, 121, (179-186), Online publication date: 1-Dec-2017. Darvishi B, Panahi Y, Ghanei M and Farahmand L (2016) Investigating Prevalence and Pattern of Long-term Cardiovascular Disorders in Sulphur Mustard-exposed Victims and Determining Proper Biomarkers for Early Defining, Monitoring and Analysis of Patients' Feedback on Therapy, Basic & Clinical Pharmacology & Toxicology, 10.1111/bcpt.12666, 120:2, (120-130), Online publication date: 1-Feb-2017. Labombarda F, Saloux E, Brouard J, Bergot E and Milliez P (2016) Heart involvement in cystic fibrosis: A specific cystic fibrosis-related myocardial changes?, Respiratory Medicine, 10.1016/j.rmed.2016.07.011, 118, (31-38), Online publication date: 1-Sep-2016. Chalkias A, Scheetz M, Gulati A and Xanthos T (2016) Periarrest intestinal bacterial translocation and resuscitation outcome, Journal of Critical Care, 10.1016/j.jcrc.2015.09.015, 31:1, (217-220), Online publication date: 1-Feb-2016. Akyüz A (2016) Association of Fetuin-A with Carotid Intima-Media Thickness and Vascular Diseases Biomarkers in Cardiovascular Disease, 10.1007/978-94-007-7678-4_16, (177-196), . Pei H, Song X, Peng C, Tan Y, Li Y, Li X, Ma S, Wang Q, Huang R, Yang D, Li D, Gao E and Yang Y (2015) TNF-α inhibitor protects against myocardial ischemia/reperfusion injury via Notch1-mediated suppression of oxidative/nitrative stress, Free Radical Bio
Referência(s)